-- Avricore Health (AVCR.V) said Tuesday that its HealthTab platform has now screened more than 3,500 patients in community pharmacies across North East and North Central London.
The company also updated its expansion strategy for its HealthTab point-of-care testing platform in the UK. HealthTab launched HbA1c testing for diabetes screening in the first quarter of this year, and UACR kidney function testing is planned for the third quarter of this year. During an initial one-month pilot of HbA1c testing, the company completed 2,295 HbA1c tests for diabetes across 57 locations, a statement said.
Avricore expects its current pilots to expand to more than 100 pharmacy sites in the second quarter, with monthly subscription revenue expected to begin in the second half of 2026.
The company, which is targeting 500 or more active UK locations by mid-2027, is forecasting a return to profitability by the third quarter of next year.
It noted that from September, all newly qualified pharmacists in England will graduate as independent prescribers, which will strengthen the clinical role of community pharmacy and supports the broader adoption of point-of-care testing infrastructure such as HealthTab.
Avricore shares closed unchanged at $0.065, on the TSX Venture Exchange on Monday.